| Powered by its proprietary gene expression platform, Elisigen's AAV gene therapy NG101 is being developed as a next-generation treatment for wAMD with lower viral doses, long-lasting therapeutic effects, and enhanced safety and cost competitiveness. |
Read Original Article (Korean)
*Note: This link will redirect you to the original source in Korean.